Biotechnology
Commented by Nico Popp on April 15th, 2025 | 09:50 CEST
Bayer, BioNTech, Defence Therapeutics: The new biotech reality opens up opportunities
The pharmaceutical sector is exempt from US tariffs. But does that mean everything will be okay for the industry? During the German Biotech Days in Heidelberg, which took place last week, market experts were cautious. Following the layoffs at the US Food and Drug Administration (FDA), there are concerns among pharmaceutical companies and biotech firms that the US could lose its leading position in research and development. According to the researchers at the conference, Europe could step into the breach under certain conditions – however, partnerships with other regions remain crucial for continued progress.
Read
Commented by André Will-Laudien on April 14th, 2025 | 08:00 CEST
Growth despite tariffs: It is all about using artificial intelligence! Novo Nordisk, NetraMark Holdings, Infineon, and Intel
The tariff policy of the Trump administration is casting a long shadow over the global economy, with ifo Institute President Clemens Fuest warning it could even trigger a new global recession. Only a handful of companies can currently afford to relax - those that manufacture entirely within the US and serve mainly domestic markets. However, the economy is highly interconnected, the recently favored globalization has ensured that. The wheel is currently turning backwards, and "local sourcing" is the new buzzword. History has shown that protectionism rarely leads to positive outcomes. It is important for investors to look closely at which policymakers truly have an understanding of economic issues without ideological distortions. Identifying these trends can lead to discovering high-potential stocks. The search is not easy, but we are here to provide support wherever possible.
Read
Commented by André Will-Laudien on April 11th, 2025 | 07:15 CEST
Trump rally boosts Vidac Pharma: Further milestones in cancer research achieved!
Humanity continues to fight relentlessly against cancer. As one of the most common causes of death, researchers have been trying to unravel the secrets of this terrible disease for more than 175 years. Meanwhile, early detection and forms of therapy have come a long way, and many patients diagnosed with cancer often go on to live for many years after their diagnosis. However, it is still too early for triumph; progress is incremental and costs time and money. The dream of biotech investors is to find the needle in the haystack. Which publicly listed company will achieve the long-awaited breakthrough? Vidac Pharma has so far achieved recognized milestones and continues its research in a targeted manner. According to a recent study on the Company, investors could see a tenfold increase over the next few years. This is reason enough for us to take a closer look!
Read
Commented by Fabian Lorenz on April 10th, 2025 | 07:30 CEST
A buying opportunity in the price horror? Novo Nordisk, BioNTech, and Defence Therapeutics!
For Novo Nordisk shareholders, who have been spoiled by price gains, the current nightmare shows no sign of ending. The notion that pharmaceutical stocks are a safe haven in turbulent times is only partially true at the moment. Novo Nordisk shares are trading at their lowest level since 2022. A buying opportunity? Yes, analysts believe, but the Trump-induced chaos is not going away anytime soon. For those looking to invest in relative strength, there is currently no getting around Defence Therapeutics. The biotech company is not affected by tariff disputes and is taking big steps towards monetization. Yesterday, there was a strong price jump. Is a takeover coming soon? For example, BioNTech has full coffers and, as the latest IPO shows, is keen to invest in companies in the oncology sector.
Read
Commented by Armin Schulz on April 9th, 2025 | 07:00 CEST
From diabetes to cancer: How Novo Nordisk, NetraMark, and BioNTech are reinventing medicine
The medicine of tomorrow is being written today – with algorithms that personalize therapies, mRNA vaccines that fight cancer, and drugs that conquer chronic diseases. While AI is revolutionizing clinical trials and shifting billion-dollar markets, biotech pioneers are fighting for dominance in precision medicine. Who is driving this transformation? Three companies are in the spotlight: Novo Nordisk, a pioneer in the fight against diabetes and obesity; NetraMark, whose AI is decoding clinical trials; and BioNTech, which is redefining oncology with mRNA. Their innovations are not just dreams of the future – they are already changing how lives are saved and extended.
Read
Commented by Armin Schulz on April 8th, 2025 | 07:30 CEST
Bayer, BioNxt Solutions, Evotec – False tariff alarm for pharma and biotech! Which stocks are worth buying?
The provisional exemption from tariffs for medicines and pharmaceutical products offers the industry a breather – but appearances are deceptive. Based on WTO rules, the exemptions protect German exports in the multi-billion-dollar US market. However, indirect risks lurk in the form of rising costs for raw materials, political unpredictability, and dependence on global supply chains. While the sector can breathe a sigh of relief in the short term, long-term trade conflicts are forcing strategic maneuvering. For Bayer, the US market is very important. BioNxt Solutions is developing disruptive drug delivery solutions, and Evotec aims to redefine drug discovery with artificial intelligence. Let's take a closer look at these three companies.
Read
Commented by Fabian Lorenz on April 4th, 2025 | 08:45 CEST
A bombshell for NetraMark shares: Is this the breakthrough for the AI biotech hidden gem?
Big news for NetraMark! The Company aims to revolutionize the clinical trial process for pharmaceutical and biotech companies - improving time efficiency, reducing costs, and increasing success rates. The software company has developed its own artificial intelligence for this purpose. Yesterday, NetraMark entered into a global partnership with a leading contract research organization (CRO). The partner is active in more than 60 countries with over 3,500 employees, and plans to use NetraMark's AI in its studies in the future. This could be the breakthrough for the AI specialist, potentially ending the stock's consolidation phase. With a market capitalization of less than CAD 100 million, the stock could have significant upside potential.
Read
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by Fabian Lorenz on April 3rd, 2025 | 07:20 CEST
Stock set for 100% rally! Evotec, thyssenkrupp, Vidac Pharma - A golden April ahead?
Can shareholders look forward to a 100% price gain soon? If analysts have their way, this could be imminent for Evotec. However, shareholders must first mark an important date in April, as the medium-term share price performance is likely to be decided then. For Vidac Pharma, analysts see even greater upside potential, making the current price weakness an interesting entry opportunity. After all, the biotech company is making operational progress. One of the surprises of the current week is thyssenkrupp. The Company is benefiting from billions being spent in defense and infrastructure. Now, it could also benefit from Trump's tariff policies. Analysts recommend buying.
Read
Commented by Juliane Zielonka on April 3rd, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, Bayer: Three ways to health and returns
The pharmaceutical industry is booming, and three companies are set to be in the spotlight in 2025: Novo Nordisk, BioNxt Solutions, and Bayer. A common goal unites all three: To improve the health of millions of patients through innovative approaches. Investors have the opportunity to participate in their success. While their strategies differ, their focus on research, new therapies, and growth makes them exciting for investors. Novo Nordisk stands out with its obesity drug Wegovy. It reduces the risk of heart disease by 57% – a potential game changer, as obesity is a major contributor to severe cardiovascular diseases. BioNxt Solutions is leveraging fresh capital and future technologies. The Company is developing novel drug delivery systems, including sublingual films, transdermal patches, and oral tablets for autoimmune diseases like multiple sclerosis. With CAD 2.5 million from a private placement, it is ready for the next step. Bayer is pushing ahead with its broad pharmaceutical offensive. In 2025, the Leverkusen-based company will launch drugs for the treatment of cardiovascular diseases, oncology, and women's health – areas with high medical demand and market potential.
Read